Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2355) 2355
Book Chapter (82) 82
Book / eBook (11) 11
Magazine Article (5) 5
Conference Proceeding (2) 2
Publication (2) 2
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1991) 1991
science & technology (1660) 1660
life sciences & biomedicine (1565) 1565
hematology (1043) 1043
male (847) 847
female (818) 818
oncology (759) 759
myeloproliferative disorders - drug therapy (740) 740
middle aged (662) 662
aged (580) 580
adult (549) 549
myeloproliferative disorders - genetics (549) 549
myeloproliferative disorders (513) 513
mutation (454) 454
biological and medical sciences (406) 406
medical sciences (400) 400
leukemia (369) 369
tumors (344) 344
animals (332) 332
janus kinase 2 - genetics (324) 324
myeloproliferative disorders - complications (303) 303
myeloproliferative disorders - pathology (299) 299
polycythemia vera (292) 292
myeloproliferative neoplasms (283) 283
myelofibrosis (277) 277
myeloproliferative disorders - diagnosis (273) 273
hematologic and hematopoietic diseases (271) 271
antineoplastic agents - therapeutic use (247) 247
aged, 80 and over (239) 239
treatment outcome (233) 233
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (221) 221
care and treatment (220) 220
prognosis (215) 215
abridged index medicus (212) 212
hemic and lymphatic diseases (208) 208
genetic aspects (206) 206
essential thrombocythemia (205) 205
cancer (200) 200
research (194) 194
risk factors (187) 187
myeloproliferative disorders - therapy (186) 186
health aspects (180) 180
bone marrow (178) 178
janus kinase 2 - antagonists & inhibitors (175) 175
protein kinase inhibitors - therapeutic use (174) 174
mice (172) 172
myeloproliferative neoplasm (167) 167
myeloproliferative disorders - metabolism (158) 158
stem cells (158) 158
analysis (157) 157
medicine & public health (155) 155
primary myelofibrosis - drug therapy (153) 153
patients (145) 145
polycythemia vera - drug therapy (141) 141
adolescent (138) 138
kinases (138) 138
thrombocythemia, essential - drug therapy (133) 133
hematology, oncology and palliative medicine (132) 132
thrombosis (132) 132
retrospective studies (130) 130
drug therapy (127) 127
myeloproliferative disorders - blood (127) 127
medicine (126) 126
signal transduction (126) 126
hydroxyurea - therapeutic use (125) 125
diagnosis (122) 122
imatinib mesylate (118) 118
jak2 (117) 117
chronic disease (116) 116
cell biology (109) 109
gene expression (108) 108
janus kinase 2 - metabolism (108) 108
pharmacology. drug treatments (107) 107
apoptosis (106) 106
hydroxyurea (106) 106
pyrimidines - therapeutic use (106) 106
primary myelofibrosis (104) 104
research article (103) 103
child (102) 102
gene mutations (102) 102
general & internal medicine (102) 102
janus kinase 2 (102) 102
protein kinase inhibitors - pharmacology (102) 102
chemotherapy (101) 101
chronic myeloid leukemia (101) 101
bone marrow - pathology (100) 100
review (100) 100
medicine, general & internal (97) 97
benzamides (96) 96
multidisciplinary sciences (96) 96
polycythemia (96) 96
science & technology - other topics (96) 96
young adult (96) 96
myeloproliferative diseases (95) 95
proteins (95) 95
follow-up studies (93) 93
antineoplastic agents (92) 92
development and progression (92) 92
neoplasms (90) 90
polycythemia vera - genetics (89) 89
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2317) 2317
German (45) 45
Japanese (37) 37
French (35) 35
Russian (15) 15
Spanish (11) 11
Czech (10) 10
Danish (7) 7
Italian (7) 7
Chinese (6) 6
Polish (6) 6
Dutch (4) 4
Portuguese (4) 4
Hungarian (3) 3
Finnish (2) 2
Turkish (2) 2
Hebrew (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
by Koppikar, Priya and Bhagwat, Neha and Kilpivaara, Outi and Manshouri, Taghi and Adli, Mazhar and Hricik, Todd and Liu, Fan and Saunders, Lindsay M and Mullally, Ann and Abdel-Wahab, Omar and Leung, Laura and Weinstein, Abby and Marubayashi, Sachie and Goel, Aviva and Gonen, Mithat and Estrov, Zeev and Ebert, Benjamin L and Chiosis, Gabriela and Nimer, Stephen D and Bernstein, Bradley E and Verstovsek, Srdan and Levine, Ross L
Nature (London), ISSN 0028-0836, 09/2012, Volume 489, Issue 7414, pp. 155 - 159
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Hematologic and hematopoietic diseases | Chemotherapy | Pharmacology. Drug treatments | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Antineoplastic agents | Myeloproliferative Disorders - enzymology | Phosphorylation | Protein Biosynthesis | Humans | Protein Multimerization | STAT Transcription Factors - metabolism | TYK2 Kinase - metabolism | Janus Kinase 1 - deficiency | TYK2 Kinase - deficiency | Myeloproliferative Disorders - pathology | Janus Kinase 1 - biosynthesis | Gene Knockdown Techniques | Janus Kinase 2 - deficiency | Janus Kinase 1 - metabolism | Granulocytes - drug effects | RNA Interference | Janus Kinase 1 - genetics | Janus Kinase 2 - metabolism | Myeloproliferative Disorders - metabolism | Granulocytes - metabolism | Janus Kinase 2 - antagonists & inhibitors | Disease Models, Animal | Cell Line | Janus Kinase 2 - genetics | Myeloproliferative Disorders - drug therapy | Enzyme Activation - drug effects | TYK2 Kinase - biosynthesis | Granulocytes - enzymology | Animals | Signal Transduction - drug effects | HSP90 Heat-Shock Proteins - antagonists & inhibitors | HSP90 Heat-Shock Proteins - metabolism | Mice | TYK2 Kinase - genetics | Drug Resistance, Neoplasm - drug effects | Enzyme inhibitors | Gene mutations | Cancer cells | Dosage and administration | Genetic aspects | Cellular signal transduction | Identification and classification | Physiological aspects | Care and treatment | Research | Myeloproliferative disorders | Cancer | Index Medicus | tyrosine kinase inhibitors | persistence | MPN | JAK2 | resistance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text The Myeloproliferative Disorders
by Campbell, Peter J and Green, Anthony R
The New England journal of medicine, ISSN 0028-4793, 12/2006, Volume 355, Issue 23, pp. 2452 - 2466
Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Multipotent Stem Cells | Myeloproliferative Disorders - diagnosis | Signal Transduction | Humans | Myeloproliferative Disorders - classification | Janus Kinase 2 - genetics | Myeloproliferative Disorders - drug therapy | Genetic Markers | Mutation | Myeloproliferative Disorders - genetics | Causes of | Myelofibrosis | Diagnosis | Drug therapy | Myeloproliferative disorders | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
by Pardanani, A
Leukemia, ISSN 0887-6924, 01/2008, Volume 22, Issue 1, pp. 23 - 30
Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Polycythemias | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Diseases of red blood cells | Myeloproliferative Disorders - enzymology | Animals | Humans | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Myeloproliferative Disorders - drug therapy | Drug Evaluation, Preclinical | Janus Kinase 2 - antagonists & inhibitors | Care and treatment | Enzyme inhibitors | Dosage and administration | Genetic aspects | Cellular signal transduction | Diagnosis | Health aspects | Myeloproliferative disorders | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Myeloproliferative disorders
by Levine, Ross L and Gilliland, D. Gary
Blood, ISSN 0006-4971, 09/2008, Volume 112, Issue 6, pp. 2190 - 2198
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Primary Myelofibrosis | History, 21st Century | History, 20th Century | Humans | Janus Kinase 2 - genetics | Myeloproliferative Disorders - drug therapy | Myeloproliferative Disorders - history | Myeloproliferative Disorders - genetics | Protein Kinase Inhibitors - therapeutic use | Myeloproliferative Disorders - etiology | Thrombocytosis | Polycythemia Vera | Janus Kinase 2 - antagonists & inhibitors | Index Medicus | Abridged Index Medicus | ASH 50th Anniversary Reviews
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text World Health Organization‐defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management
by Shomali, William and Gotlib, Jason
American journal of hematology, ISSN 0361-8609, 10/2019, Volume 94, Issue 10, pp. 1149 - 1167
Life Sciences & Biomedicine | Hematology | Science & Technology | Eosinophilia - therapy | Prognosis | Humans | Middle Aged | Symptom Assessment | Male | Antineoplastic Agents - therapeutic use | Eosinophilia - epidemiology | Myelodysplastic Syndromes - blood | Adrenal Cortex Hormones - therapeutic use | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Myeloproliferative Disorders - blood | Receptor, Platelet-Derived Growth Factor alpha - antagonists & inhibitors | Adult | Female | mRNA Cleavage and Polyadenylation Factors - genetics | Eosinophilia - diagnosis | Myelodysplastic Syndromes - drug therapy | mRNA Cleavage and Polyadenylation Factors - antagonists & inhibitors | Myeloproliferative Disorders - diagnosis | Hematologic Neoplasms - diagnosis | Eosinophilia - etiology | World Health Organization | Risk Assessment | Janus Kinase 2 - genetics | Immunophenotyping | In Situ Hybridization, Fluorescence | Myeloproliferative Disorders - drug therapy | Bone Marrow Examination | Myelodysplastic Syndromes - diagnosis | Clone Cells - pathology | Hematologic Neoplasms - blood | Oncogene Proteins, Fusion - genetics | Receptor, Platelet-Derived Growth Factor alpha - genetics | Hematologic Neoplasms - drug therapy | Oncogene Proteins, Fusion - antagonists & inhibitors | Aged | Disease Management | Corticoids | Imatinib | Eosinophilic leukemia | Leukocytes (eosinophilic) | Stem cell transplantation | Cytotoxicity | Hydroxyurea | Hybridization | Eosinophilia | Hematopoietic stem cells | Hemopoiesis | Chemotherapy | Janus kinase 2 | Peripheral blood | Cytogenetics | Interferon | Diagnosis | Fibroblast growth factor receptor 1 | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML
by Saenz, Dyana T and Fiskus, Warren and Manshouri, Taghi and Mill, Christopher P and Qian, Yimin and Raina, Kanak and Rajapakshe, Kimal and Coarfa, Cristian and Soldi, Raffaella and Bose, Prithviraj and Borthakur, Gautam and Kadia, Tapan M and Khoury, Joseph D and Masarova, Lucia and Nowak, Agnieszka J and Sun, Baohua and Saenz, David N and Kornblau, Steven M and Horrigan, Steve and Sharma, Sunil and Qiu, Peng and Crews, Craig M and Verstovsek, Srdan and Bhalla, Kapil N
Leukemia, ISSN 0887-6924, 2018, Volume 33, Issue 6, pp. 1373 - 1386
Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Apoptosis -